reports
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Damien Choplain
- Martial Descoutures
Argenx : Product ramp-up continues
>Q1 in line on sales, below on EBIT - Q1 sales grew by 83% y-o-y and 6% q-o-q to $ 398m (US $ 347m, Japan $ 18m and EMEA $ 31m), reflecting the strong medical need in myasthenia gravis, the quality of products (i.e. Vyvgart and Vyvgart Hytrulo), as well as the excellent execution of the commercial rollout. The product should remain on this growth trajectory to achieve peak sales estimated at $ 11bn (vs the consensus at $ 11bn) in 2035, driven by the recent launch of ...
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: 1Q24 results on track, all eyes set on CIDP
This morning argenx reported its 1Q24 update, highlighting $ 398m sales and its pipeline progress. Mgmt is fully focused on expanding its commercial footprint into CIDP (PDUFA: June 21). Meanwhile, AAV was scrapped from the pipeline and systemic sclerosis (SSC) added. We maintain our € 435 TP and Buy rating.
- Damien Choplain
- Martial Descoutures
Argenx : La montée en puissance des produits se poursuit
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
argenx Reports First Quarter 2024 Financial Results and Provides Busin...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its fi...
- David Seynnaeve
- PhD
argenx - Q1 beat on CSS
• Argenx published its Q1 update in which VYVGARD revenues slightly beat CSS by 2%• Two key news items: 1/ filing for the pre-filled syringe syringe for gMG and CIDP to be submitted in Q2 24 and 2/ decision to discontinue the planned development of efgartigimod in ANCA-associated vasculitis (AAV) following risk assessment of all ongoing studies based on learnings from ADDRESS and ADVANCE SC studies. CIDP PDUFA target action date of June 21 reiterated• Cash position stood at USD 3.1bn end of Marc...
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
UCG UNICREDIT S.P.A.
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- ING Helpdesk
Benelux Morning Notes
AB InBev: Busy BEES. Ahold Delhaize: Small beat, comforting confirmation of 2024 guidance. AMG: 1Q24 better than expected, FY guidance intact, strategic projects on schedule. Bekaert: Soft start to the year with 7% sales miss, FY guidance maintained. Euronav: Transformation at full speed. Marel: Another lacklustre quarter. Montea: 2025 guidance raised, valuations moving into positive territory. SBM Offshore: In-line Q1 trading update. Sif Group: Preview - normal quarter e...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Wim Hoste
AB InBev FIRST LOOK: solid start of the year with 1Q EBITDA +5.4%
Despite the continued impact from Bud Light in the US, 1Q EBITDA was up 5.4% and above our and CSS forecasts (of respectively +0.2% and +1.9%). Comparatives will significantly ease in the US going forward and ABI reiterated FY24 guidance of 4-8% EBITDA growth (KBCS +6%, CSS +8%). We still appreciate ABI for its leadership positions in the global beer market, high intrinsic profitability and LT growth prospects in its emerging markets businesses. Deleveraging is on track and with valuation multip...
- Robert Jan Vos
Anheuser-Busch InBev : Solid Q1 2024, and, as expected, outlook mainta...
>Solid Q1 2024 with revenue, EBITDA and net profit ahead of expectations - ABI reported organic volume growth of -0.6% in Q1 2024 (ABNe: 1e2.4%, consensus: 1e1.0%). Revenue growth was 2.6% (ABNe: 3.6%, consensus: 2.6%) to $ 14,547m (ABNe: $ 14,332m, consensus: $ 14,432m). EBITDA growth was 5.4% (ABNe: 2.0%, consensus: 1.9%) to $ 4,987m (ABNe: $ 4,766m, consensus: $ 4,828m). Organic volume growth was ahead of expectations in North America, Middle Americas, and EMEA and ...
AB InBev Reports First Quarter 2024 Results
BRUSSELS--(BUSINESS WIRE)-- Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: ABI Strategic Priorities - English (Graphic: Business Wire) Regulated information1 “The strength of the beer category, our diversified global footprint and the continued momentum of our megabrands delivered another quarter of broad-based top- and bottom-line growth. We are encouraged by our results to start the year, and the consistent execution by our teams and partners reinforces our confidence in delivering on our 2024 growth a...
AB InBev publie les résultats du premier trimestre 2024
BRUXELLES--(BUSINESS WIRE)-- Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : ABI Strategic Priorities - French (Graphic: Business Wire) Information réglementée1 « La force de la catégorie bière, notre empreinte mondiale diversifiée et le maintien de la dynamique de nos méga-marques nous ont permis de réaliser à nouveau une croissance généralisée des produits et des bénéfices au cours de ce trimestre. Nous sommes encouragés par nos résultats pour commencer l’année, et l’exécution co...
- Fernand de Boer
AB InBev - A good start to the year
• Q1 24 results exceeding expectations, with a good performance in most regions with stable to higher market shares• EBITDA increased by 5.4% organically, providing confidence that FY growth will land at the higher end of the 4-8% range, or even above. Hence, we expect consensus EBITDA estimate to rise by 1-2% based on these numbers• We reiterate our Buy recommendation and 12m TP of EUR 68
argenx announces results of Annual General Meeting of Shareholders
argenx announces results of Annual General Meeting of Shareholders May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for the financial year ending...
argenx to Present at BofA Securities 2024 Health Care Conference
argenx to Present at BofA Securities 2024 Health Care Conference May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at . A replay of the webcast will be availabl...
- Hilde Van Boxstael
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.